tradingkey.logo

Collplant Biotechnologies Ltd

CLGN
View Detailed Chart
0.800USD
+0.050+6.65%
Close 02/06, 16:00ETQuotes delayed by 15 min
10.22MMarket Cap
LossP/E TTM

Collplant Biotechnologies Ltd

0.800
+0.050+6.65%
Intraday
1m
30m
1h
D
W
M
D

Today

+6.65%

5 Days

-57.68%

1 Month

-44.83%

6 Months

-71.12%

Year to Date

-42.86%

1 Year

-78.48%

View Detailed Chart

Key Insights

Collplant Biotechnologies Ltd's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 121 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 11.50.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Collplant Biotechnologies Ltd's Score

Industry at a Glance

Industry Ranking
121 / 392
Overall Ranking
257 / 4521
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Collplant Biotechnologies Ltd Highlights

StrengthsRisks
CollPlant Biotechnologies Ltd, formerly known as Collplant Holdings Ltd, is a company dealing in aesthetic medicine and regenerative medicine based in Israel. The company provides products and technologies for broadly understood regenerative medicine, including tissue regeneration and organ production. The technology is based on plants and is based on the production of collagen type I (rhCollagen).
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 72.24% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 515.00K.
Overvalued
The company’s latest PE is -0.78, at a high 3-year percentile range.
Held by James Simons
Star Investor James Simons holds 21.90K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.72.

Analyst Rating

Based on 2 analysts
Buy
Current Rating
11.500
Target Price
+1433.33%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Collplant Biotechnologies Ltd News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Collplant Biotechnologies Ltd Info

CollPlant Biotechnologies Ltd, formerly known as Collplant Holdings Ltd, is a company dealing in aesthetic medicine and regenerative medicine based in Israel. The company provides products and technologies for broadly understood regenerative medicine, including tissue regeneration and organ production. The technology is based on plants and is based on the production of collagen type I (rhCollagen).
Ticker SymbolCLGN
CompanyCollplant Biotechnologies Ltd
CEORotem (Eran)
Websitehttps://www.collplant.com
KeyAI